| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0887-7963(03)00022-1 |
| P698 | PubMed publication ID | 12881783 |
| P2093 | author name string | John R Hess | |
| Ray Armand | |||
| P2860 | cites work | Epidemiology of trauma deaths: a reassessment | Q28235326 |
| Hemostatic drugs | Q28277099 | ||
| Coagulation disorders in liver disease | Q33341818 | ||
| Prophylactic platelet administration during massive transfusion. A prospective, randomized, double-blind clinical study | Q33452902 | ||
| Replacement of massive blood loss | Q33503332 | ||
| Hypotensive resuscitation during active hemorrhage: impact on in-hospital mortality | Q33959509 | ||
| Management of massive blood loss: a template guideline | Q34096593 | ||
| Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries | Q34324044 | ||
| Use of recombinant factor VIIa in hereditary bleeding disorders | Q34403995 | ||
| Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy | Q34522223 | ||
| Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure | Q34564920 | ||
| Potential role for rFVIIa in transfusion medicine | Q34564930 | ||
| Scientific priorities and strategic planning for resuscitation research and life saving therapy following traumatic injury: report of the PULSE Trauma Work Group | Q34667393 | ||
| Early intensive care unit intervention for trauma care: what alters the outcome? | Q35010132 | ||
| Recombinant factor VIIa for control of hemorrhage: early experience in critically ill trauma patients | Q35138036 | ||
| The need for highly purified products to treat hemophilia B. | Q40420343 | ||
| Physiologic rationale for abbreviated laparotomy | Q41590392 | ||
| Damage control for abdominal trauma | Q41590412 | ||
| Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries | Q43575604 | ||
| Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate | Q44234275 | ||
| Recombinant activated factor VII for adjunctive hemorrhage control in trauma | Q44472174 | ||
| The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries | Q45888438 | ||
| Epidemiology of trauma: military experience | Q46212152 | ||
| Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. | Q53896354 | ||
| Treatment of traumatic bleeding with recombinant factor VIIa. | Q55033461 | ||
| Dry fibrin sealant dressings reduce blood loss, resuscitation volume, and improve survival in hypothermic coagulopathic swine with grade V liver injuries. | Q64892728 | ||
| Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient | Q69464615 | ||
| Oxygen-linked hydrogen ion binding of human hemoglobin. Effects of carbon dioxide and 2,3-diphosphoglycerate. II. Studies on whole blood | Q71787342 | ||
| Predicting life-threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidoses revisited | Q73434813 | ||
| Different hypotensive responses to intravenous bovine and human thrombin preparations in swine | Q73570332 | ||
| Hypothermic coagulopathy in trauma: effect of varying levels of hypothermia on enzyme speed, platelet function, and fibrinolytic activity | Q74593077 | ||
| Disseminated intravascular coagulation | Q93925327 | ||
| P433 | issue | 3 | |
| P921 | main subject | blood coagulation disease | Q890200 |
| P304 | page(s) | 223-231 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | Transfusion Medicine Reviews | Q15758511 |
| P1476 | title | Treating coagulopathy in trauma patients | |
| P478 | volume | 17 |
| Q26752287 | A recommended early goal-directed management guideline for the prevention of hypothermia-related transfusion, morbidity, and mortality in severely injured trauma patients |
| Q28074982 | A systematic review on the rotational thrombelastometry (ROTEM®) values for the diagnosis of coagulopathy, prediction and guidance of blood transfusion and prediction of mortality in trauma patients |
| Q41868264 | Acute traumatic coagulopathy: Incidence, risk stratification and therapeutic options. |
| Q46166562 | Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway? |
| Q41968352 | Advances in military, field, and austere transfusion medicine in the last decade |
| Q38478829 | Blood transfusion rates in the care of acute trauma. |
| Q41907799 | Blood-banking techniques for plateletpheresis in swine |
| Q46883897 | Buffering and dilution in red blood cell storage |
| Q28072443 | Coagulation complications following trauma |
| Q50708976 | Coagulopathy in multiple trauma: new aspects of therapy |
| Q39454234 | Coagulopathy in the Setting of Mild Traumatic Brain Injury: Truths and Consequences |
| Q35858644 | Combat: Initial Experience with a Randomized Clinical Trial of Plasma-Based Resuscitation in the Field for Traumatic Hemorrhagic Shock |
| Q37783356 | Comparison of platelet transfusion as fresh whole blood versus apheresis platelets for massively transfused combat trauma patients (CME). |
| Q38081940 | Contralateral haematoma secondary to decompressive craniectomy performed for severe head trauma: a descriptive study of 15 cases |
| Q33962418 | Conventional blood banking and blood component storage regulation: opportunities for improvement |
| Q34120257 | Creation, implementation, and maturation of a massive transfusion protocol for the exsanguinating trauma patient |
| Q36546261 | Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients |
| Q36704910 | Damage control surgery for the patient who has experienced multiple traumatic injuries |
| Q34334830 | Differentiating disseminated intravascular coagulation (DIC) with the fibrinolytic phenotype from coagulopathy of trauma and acute coagulopathy of trauma-shock (COT/ACOTS). |
| Q53087708 | Does the storage duration of blood products affect outcomes in critically ill patients? |
| Q51633018 | Effects of an acidic environment on coagulation dynamics. |
| Q37390952 | Evolution of the role of army transfusion services in the management of trauma patients and battle casualties with massive hemorrhage. |
| Q50729886 | Experiences with frozen blood products in the Netherlands military |
| Q85193685 | Fibrinogen concentrate for management of bleeding |
| Q37368512 | Fibrinogen metabolic responses to trauma |
| Q33810788 | Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy. |
| Q53460009 | Fluid resuscitation in haemorrhagic shock in combat casualties. |
| Q53226045 | Fresh whole blood transfusions in coalition military, foreign national, and enemy combatant patients during Operation Iraqi Freedom at a U.S. combat support hospital. |
| Q43108387 | Functional capacity of reconstituted blood in 1:1:1 versus 3:1:1 ratios: a thrombelastometry study |
| Q50045370 | Goal-directed Hemostatic Resuscitation for Trauma Induced Coagulopathy : Maintaining Homeostasis |
| Q34642910 | Haemorrhage control in severely injured patients |
| Q47722397 | Haemostatic profile of reconstituted blood in a proposed 1:1:1 ratio of packed red blood cells, platelet concentrate and four different plasma preparations. |
| Q46060644 | How we treat: management of life-threatening primary postpartum hemorrhage with a standardized massive transfusion protocol |
| Q36615864 | Increase in activated protein C mediates acute traumatic coagulopathy in mice |
| Q50710896 | Massive blood transfusion and outcome in 1062 polytrauma patients: a prospective study based on the Trauma Registry of the German Trauma Society |
| Q36284640 | Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma |
| Q35578975 | Methods for improved hemorrhage control |
| Q39163730 | Modelling the effects of blood component storage lesions on the quality of haemostatic resuscitation in massive transfusion for trauma |
| Q37660537 | New evidence in trauma resuscitation - is 1:1:1 the answer? |
| Q35578932 | Optimizing the use of blood products in trauma care. |
| Q36396010 | Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients |
| Q33375346 | Pharmacology and clinical use of recombinant activated factor seven in neurosciences |
| Q37732197 | Plasma first in the field for postinjury hemorrhagic shock |
| Q38628454 | Platelet microparticles in cryopreserved platelets: Potential mediators of haemostasis |
| Q41624242 | Prevalence and Associated Factors of Acute Traumatic Coagulopathy; a Cross Sectional Study |
| Q50707061 | Procedure for critical nonsurgical bleeding |
| Q36492564 | Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. |
| Q40153017 | Relative effects of plasma, fibrinogen concentrate, and factor XIII on ROTEM coagulation profiles in an in vitro model of massive transfusion in trauma |
| Q41096308 | Resuscitating PROPPRly |
| Q35174893 | Resuscitation and transfusion principles for traumatic hemorrhagic shock |
| Q58735325 | Resuscitation of Endotheliopathy and Bleeding in Thoracic Aortic Dissections: The VIPER-OCTA Randomized Clinical Pilot Trial |
| Q34372103 | Revisiting early postinjury mortality: are they bleeding because they are dying or dying because they are bleeding? |
| Q48043563 | Should whole blood replace the shock pack? |
| Q45028730 | The US military experience with fresh whole blood during the conflicts in Iraq and Afghanistan |
| Q38001075 | The use of trauma transfusion pathways for blood component transfusion in the civilian population: a systematic review and meta-analysis |
| Q38839847 | The use of viscoelastic haemostatic assays in goal-directing treatment with allogeneic blood products - A systematic review and meta-analysis |
| Q42153351 | Theoretical modelling of fibrinogen supplementation with therapeutic plasma, cryoprecipitate, or fibrinogen concentrate |
| Q34563820 | Tips and tricks for the trauma patient |
| Q35559379 | Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. |
| Q36230698 | Transfusion practice in massively bleeding patients: time for a change? |
| Q38298649 | Transfusion practices in trauma |
| Q34991206 | Transfusion protocol in trauma |
| Q37591799 | Transfusion therapy in hemorrhagic shock |
| Q47904161 | Traumatic deaths at hospital: analysis of preventability and lessons learned |
| Q37900080 | Update and new developments in the management of the exsanguinating patient |
| Q50664916 | Use of recombinant activated factor VII to arrest uncontrolled bleeding: a case series. |
| Q35077973 | Warm fresh whole blood is independently associated with improved survival for patients with combat-related traumatic injuries |
| Q46933785 | Warm storage of whole blood for 72 hours |
| Q38813905 | Whole blood for hemostatic resuscitation of major bleeding |
| Q38831832 | Will pathogen reduction of blood components harm more people than it helps in developed countries? |
| Q79345654 | [Prerequisites of a functional haemostasis. What must be considered at the scene of an accident, in the emergency room and during an operation?] |
| Q81137611 | [Treatment of hemorrhagic shock. New therapy options] |
Search more.